Malignant Neoplasm of Thyroid Stage I, Malignant Neoplasm of Thyroid Stage II
Conditions
Keywords
differentiated thyroid cancer, THS suppression, metformin
Brief summary
Differentiated thyroid cancer is the most common neoplasm of endocrine system. After surgery and radioiodine treatment, thyroid stimulating hormone (TSH) suppression is the main goal which is achieved with levothyroxine treatment. Levothyroxine causes increased thyroid hormones which can have negative impact on bone and cardiovascular system. Anecdotal reports have shown that metformin can induce TSH suppression without change in T3 and T4 concentration. The purpose of this study was to prescribe metformin as additional drug to levothyroxin in order to decrease levothyroxine dosage.
Interventions
DRUGMetformin
in case group metformin is added to levothyroxine and levothyroxine is decreased by 30% .in control group levothyroxine is reduced by 30% and no metformin is added to the regimen.
Sponsors
Mashhad University of Medical Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 80 Years
Healthy volunteers
No
Inclusion criteria
* papillary or follicular thyroid cancer * stage 1 or 2 according to TNM system version 6 * surgery and radioiodine treatment * levothyroxine suppression treatment
Exclusion criteria
* cardiopulmonary failure * liver failure * renal failure * pregnancy * drugs (colestyramin, sucralfate, phenobarbital, phenytoin, carbamazepin, rifampin, amiodarone, chloroquin, androgens, sertraline, frusemide, heparin)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| TSH | 3 months |
Secondary
| Measure | Time frame |
|---|---|
| freeT3,freeT4 | 3months |
Countries
Iran
Outcome results
None listed